Tag: Sensorion
Sensorion announces its participation in the Van Lanschot Kempen’s Life Sciences conference – 04/10/2024 at 07:30
Sensorion announces its participation in the conference Van Lanschot Kempen’s Life Sciences Montpellier, April 10, 2024, at 7:30 a.m. CET – Sensorion (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company…
Sensorion: Completion of a private placement
Receive the value of the day for free every morning The data collected is essential for this processing and is intended for the relevant services of BFM Bourse and, where…
Sensorion: financing of 15 million euros, a cash horizon extended until the end of 2025 – 04/08/2024 at 08:42
(AOF) – Sensorion announces the completion of a placement for a gross amount of 15 million euros reserved for specific categories of investors, through the issue of 24.57 million ordinary…
Sensorion announces financing of 15 million euros, and extends its cash horizon until the end of 2025 – 04/08/2024 at 07:30
Sensorion announces financing of 15 million euros, and extends its cash horizon until the end of 2025 • Support from existing investors, including Redmile Group, Invus, Sofinnova Partners and a…
Sensorion: an analyst begins monitoring
JB.A. Published on 03/21/2024 at 2:05 p.m. Stifel initiates coverage of Sensorion with a ‘buy’ recommendation and a target of 1.50 euros,…
Sensorion: 37 million in cash, visibility until mid-2025
(AOF) – Sensorion has net available cash of 37 million euros, and says it is capable of meeting its cash flow needs beyond the next twelve months, i.e. until the…
Sensorion on the rise after encouraging results against hearing loss – 03/11/2024 at 10:59
(AOF) – Sensorion (+5.83% to 0.92 euros) is up after announcing positive results for its Sens-401 product. The clinical-stage biotech specializing in the development of novel therapies to restore, treat…
Sensorion: results of a study in hearing loss
(CercleFinance.com) – Sensorion announces the achievement of the primary endpoint in the phase 2a clinical study evaluating SENS-401 in the indication of preservation of residual hearing after cochlear implantation. This…
Sensorion: Results of a study in hearing loss
Read also (CercleFinance.com) – Sensorion announces the achievement of the primary endpoint in the phase 2a clinical study evaluating SENS-401 in the indication of preservation of residual hearing after cochlear…
Sensorion announces that the primary endpoint of the Phase 2a clinical study of SENS-401 in the preservation of residual hearing has been achieved – 03/11/2024 at 07:30
Sensorion announces that the primary endpoint of the Phase 2a clinical study of SENS-401 in the preservation of residual hearing has been achieved•The presence of SENS-401 is confirmed in the…
Sensorion: completion of a private placement
(CercleFinance.com) – Sensorion announces the completion of a placement of 50.5 million euros reserved for specific categories of European and American investors, through the issue of 88,594,737 new ordinary shares…
Sensorion announces successful financing of 50.5 million euros with the participation of leading new and existing European and American investors specializing in the field of life sciences – 02/09/2024 at 07:30
Sensorion announces successful €50.5 million financing with participation from leading new and existing European and American life sciences investorsSupport from existing investors: Redmile Group, Invus and Sofinnova PartnersParticipation of leading…